SDGR

Schrodinger, Inc. (SDGR) 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. Schrodinger, Inc. operates a dual business model: (1) a Software segment licensing physics-based computational platforms for drug and materials discovery to biopharmaceutical and industrial customers; and (2) a Drug Discovery segment advancing proprietary and collaborative therapeutic programs. The company is a large accelerated filer with its common stock traded on the Nasdaq Global Select Market.

Key Financial Metrics

Note: The 2025 net loss includes a non-cash gain of $48.2 million from the change in fair value of equity investments (primarily Structure Therapeutics).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 23% year-over-year. Drug discovery revenue more than doubled (+107%) driven by the initiation of the Novartis collaboration services and progress on existing collaborations. Software revenue grew 11%, with hosted software revenue up 28% while on-premise revenue declined 2% due to timing of multi-year contracts.
• Cost Reductions: Operating expenses decreased 9% to $309.5 million. Research and Development (R&D) expenses dropped 14% to $173.1 million, largely due to the discontinuation of the SGR-2921 program and a May 2025 restructuring that reduced headcount by approximately 60 employees (7%).
• Collaboration Milestones: In November 2024, the company entered a major collaboration with Novartis, receiving a $150.0 million upfront payment in January 2025. The company is eligible for up to $2.272 billion in total milestones under this agreement.
• Equity Investment Gains: A significant non-cash gain of $48.2 million was recorded from the mark-to-market adjustment of the equity investment in Structure Therapeutics, significantly reducing the reported net loss.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue investing in proprietary drug discovery programs (SGR-1505 and SGR-3515) and the computational platform. The company does not intend to initiate additional independent clinical trials beyond the current Phase 1 programs, preferring to seek strategic partnerships for advancement.
• Liquidity: As of December 31, 2025, the company held $402.3 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 24 months.
• Key Risks:
  • Profitability: The company has a history of significant operating losses and expects to incur losses over the next several years.
  • Clinical Development: Success depends on the safety and efficacy of proprietary candidates (SGR-1505, SGR-3515) and the ability of collaborators to advance programs. The SGR-2921 program was discontinued in August 2025 due to safety concerns.
  • Regulatory & Pricing: Risks include FDA regulatory changes, potential delays in approvals, and legislative pressures on drug pricing (e.g., Inflation Reduction Act, potential Most-Favored-Nation pricing).
  • Customer Concentration: A significant portion of revenue comes from the life sciences industry; the top 20 pharma cohort accounted for 37% of software revenue in 2025.

Investor Verification Checklist

• Novartis Collaboration: Verify the recognition of the $150M upfront payment and the timeline for potential milestone revenue recognition.
• SGR-1505 Clinical Data: Review the Phase 1 data for the MALT1 inhibitor (SGR-1505), specifically the 25% overall response rate and safety profile in relapsed/refractory B-cell malignancies.
• Restructuring Impact: Confirm the realization of the estimated $30 million in annualized cost savings from the May 2025 workforce reduction.
• Equity Valuation: Assess the sustainability of the $48.2 million non-cash gain from Structure Therapeutics and its impact on future earnings volatility.
• Software Transition: Monitor the shift from on-premise to hosted software revenue recognition, which may impact short-term revenue timing.